Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS. Wang L, et al. Among authors: van de ven m, van den heuvel mm, van der heijden ms. Eur Urol. 2017 Jun;71(6):858-862. doi: 10.1016/j.eururo.2017.01.021. Epub 2017 Jan 17. Eur Urol. 2017. PMID: 28108151
Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.
Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, Linn SC. Vollebergh MA, et al. Among authors: van den heuvel mm. J Thorac Oncol. 2010 Dec;5(12):1939-48. doi: 10.1097/JTO.0b013e3181f77a39. J Thorac Oncol. 2010. PMID: 21102259 Free article.
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R. Majewski IJ, et al. J Pathol. 2013 Jul;230(3):270-6. doi: 10.1002/path.4209. J Pathol. 2013. PMID: 23661334
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF, Bernards R. Groenendijk FH, et al. Among authors: van der burg e, van den heuvel mm. Int J Cancer. 2015 Mar 15;136(6):1434-44. doi: 10.1002/ijc.29113. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25080865 Free PMC article. Clinical Trial.
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, Velds A, Nieuwland M, van den Heuvel MM, Kerkhoven RM, Wessels LF, Broeks A, van Rhijn BW, Bernards R, van der Heijden MS. Groenendijk FH, et al. Among authors: van rhijn bw, van den heuvel mm, van der heijden ms. Eur Urol. 2016 Mar;69(3):384-8. doi: 10.1016/j.eururo.2015.01.014. Epub 2015 Jan 27. Eur Urol. 2016. PMID: 25636205
FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
Theelen WS, Mittempergher L, Willems SM, Bosma AJ, Peters DD, van der Noort V, Japenga EJ, Peeters T, Koole K, Šuštić T, Blaauwgeers JL, van Noesel CJ, Bernards R, van den Heuvel MM. Theelen WS, et al. Among authors: van noesel cj, van den heuvel mm, van der noort v. J Pathol Clin Res. 2016 Aug 13;2(4):223-233. doi: 10.1002/cjp2.51. eCollection 2016 Oct. J Pathol Clin Res. 2016. PMID: 27785367 Free PMC article.
Chemoradiation therapy in nonsmall cell lung cancer.
Baas P, Belderbos JS, van den Heuvel M. Baas P, et al. Curr Opin Oncol. 2011 Mar;23(2):140-9. doi: 10.1097/CCO.0b013e328341eed6. Curr Opin Oncol. 2011. PMID: 21178617 Review.
Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating.
van den Heuvel MM, Uyterlinde W, Vincent AD, de Jong J, Aerts J, Koppe F, Knegjens J, Codrington H, Kunst PW, Dieleman E, Verheij M, Belderbos J. van den Heuvel MM, et al. Radiother Oncol. 2014 Jan;110(1):126-31. doi: 10.1016/j.radonc.2013.10.009. Epub 2013 Nov 11. Radiother Oncol. 2014. PMID: 24225233 Clinical Trial.
172 results